<p><b><i>The idiopathic inflammatory myositis market is set for significant growth driven by the introduction of new therapies such as dazukibart (PF 06823859), efgartigimod, SAPHNELO (anifrolumab), brepocitinib, and HIZENTRA, among others. Furthermore, the increasing number of cases, influenced by risk factors like genetic predisposition, viral infections, and UV exposure, is anticipated to further heighten the demand for effective treatments.</i></b></p>
<p><span class="legendSpanClass"><span class="xn-location">LAS VEGAS</span></span>, <span class="legendSpanClass"><span class="xn-chron">Jan. 6, 2025</span></span> /PRNewswire/ -- DelveInsight's <b><a href="https://www.delveinsight.com/report-store/idiopathic-inflammatory-myositis-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr" rel="nofollow" target="_blank">Idiopathic Inflammatory Myositis Market Insights</a></b> report includes a comprehensive understanding of current treatment practices, idiopathic inflammatory myositis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [<span class="xn-location">the United States</span>, the EU4 (<span class="xn-location">Germany</span>, <span class="xn-location">France</span>, <span class="xn-location">Italy</span>, and <span class="xn-location">Spain</span>) and the <span class="xn-location">United Kingdom</span>, and Japan]. </p>

<div dir="ltr" id="prni_dvprnejpg1d0dleft" style="width: 100%; text-align: left;"><img align="middle" alt="DelveInsight Logo" id="prnejpg1d0dleft" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" style="width: 400px; height: 181px;" title="DelveInsight Logo"></img></div><p><b>Key Takeaways from the Idiopathic Inflammatory Myositis Market Report</b></p>
<ul type="disc"><li>According to DelveInsight's analysis, the market size for idiopathic inflammatory myositis was found to be <b><span class="xn-money">USD 447 million</span></b> in the 7MM in 2023.</li><li>As per the estimates, among the therapies currently in use, immunoglobulins held the largest market share, generating approximately <b><span class="xn-money">USD 270.3 million</span></b> in revenue in 2023 across the 7MM.</li><li>The total diagnosed prevalent cases of idiopathic inflammatory myositis in the 7MM were approximately <b><span class="xn-money">191K</span></b> cases in 2023, which are expected to increase during the forecast period (2020–2034).</li><li>Leading idiopathic inflammatory myositis companies such as <b>Pfizer, Argenx, AstraZeneca, Priovant Therapeutics, CSL Behring, Abcuro, Inc., Amgen, Janssen, Galapagos NV, Immunoforge, Merck KGaA (EMD Serono Research &amp; Development Institute), Cabaletta Bio, Restem,</b> and others are developing novel idiopathic inflammatory myositis drugs that can be available in the idiopathic inflammatory myositis market in the coming years.</li></ul><ul type="disc"><li>The promising idiopathic inflammatory myositis therapies in the pipeline include <b>Dazukibart, Efgartigimod, SAPHNELO (Anifrolumab), Brepocitinib, HIZENTRA, Empasiprubart, Ulviprubart (ABC008), Daxdilimab, Nipocalimab, Froniglutide (PF1801), GLPG3667, Enpatoran (M5049), CABA-201, Umbilical Cord Lining Stem Cells (ULSC), </b>and others.</li><li>In <b><span class="xn-chron">November 2024</span></b>, argenx decided to continue developing <b>efgartigimod SC</b> (efgartigimod alfa and hyaluronidase-qvfc) in the ongoing Phase 2/3 ALKIVIA study for adults with idiopathic inflammatory myopathies. The decision was based on topline results from the Phase 2 portion, which <b>met the primary endpoint</b> by demonstrating a statistically significant treatment effect in the mean total improvement score (TIS) at Week 24. Additionally, improvements were observed across all six core set measures of the TIS, favoring efgartigimod SC over placebo.</li></ul><p>Discover which therapies are expected to grab the major idiopathic inflammatory myositis market share @ <b><a href="https://www.delveinsight.com/sample-request/idiopathic-inflammatory-myositis-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr" rel="nofollow" target="_blank">Idiopathic Inflammatory Myositis Market Report</a></b></p>
<p><b>Idiopathic Inflammatory Myositis Overview</b></p>
<p>Idiopathic inflammatory myositis (IIM) is a rare autoimmune disorder that leads to muscle inflammation, causing muscle weakness, and in some cases, skin rashes. It encompasses several conditions, including polymyositis, dermatomyositis, inclusion body myositis, and necrotizing autoimmune myopathy. The exact cause of IIM is unknown, but it is thought to be triggered by an autoimmune response where the body's immune system mistakenly attacks its own muscle tissues. Genetic, environmental, and infectious factors may contribute to the development of the condition.</p>
<p>Symptoms of IIM typically include progressive muscle weakness, especially in the upper arms, thighs, neck, and shoulders. Patients may also experience fatigue, difficulty swallowing (dysphagia), joint pain, and in the case of dermatomyositis, a characteristic rash. The rash can appear as red or purple discoloration over the eyelids (heliotrope rash) or a raised, scaly rash on the knuckles (Gottron's papules).</p>
<p>Diagnosis involves a combination of clinical examination, blood tests, muscle biopsy, and imaging studies. Blood tests often reveal elevated levels of muscle enzymes, such as creatine kinase (CK), which indicate muscle damage. Electromyography (EMG) can assess muscle electrical activity, while MRI may show muscle inflammation. In certain cases, a muscle biopsy is required to confirm the diagnosis by evaluating tissue samples for signs of inflammation and muscle damage. Identifying specific autoantibodies can also assist in diagnosis and help determine the subtype of IIM.</p>
<p><b>Idiopathic Inflammatory Myositis Epidemiology Segmentation</b></p>
<p>The idiopathic inflammatory myositis epidemiology section provides insights into the historical and current idiopathic inflammatory myositis patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.</p>
<p>The idiopathic inflammatory myositis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:</p>
<ul type="disc"><li>Total Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis </li><li>Type-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory </li><li>Gender-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory </li><li>Age-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis   </li></ul><p><b>Idiopathic Inflammatory Myositis Treatment Market </b></p>
<p>Idiopathic inflammatory myositis, while classified as a rare disease, has become more widely recognized in recent years, thanks to advancements in diagnostic methods, increased awareness among healthcare professionals, and a deeper understanding of the disease. This growing recognition, along with the rising number of diagnosed cases, could fuel the IIM market growth as more patients seek treatment. The management of this condition generally involves a combination of <b>pharmacological treatments and supportive therapies</b>, with the main goals being to reduce inflammation, control symptoms, preserve muscle function, and prevent complications.</p>
<p>The treatment landscape for idiopathic inflammatory myositis has evolved to include a comprehensive approach, combining medications, physical therapy, and supportive care. First-line treatments often include high-dose corticosteroids like <b>prednisone or ACTHAR GEL</b> to control inflammation and immune responses. Immunosuppressants, such as <b>methotrexate, azathioprine, and tacrolimus</b>, are commonly used to minimize long-term steroid use.</p>
<p>When response to initial therapies is inadequate, biologics like <b>rituximab </b>may be used for targeted immune suppression. Physical therapy remains a crucial component for maintaining muscle strength and function, while additional supportive treatments like <b>NSAIDs and sun protection</b> help alleviate symptoms. <b>Intravenous Immunoglobulin (IVIG) therapy, with OCTAGAM 10%</b> approved in the US and <span class="xn-location">Europe</span> and VENOGLOBULIN-IH 5% available in <span class="xn-location">Japan</span>, is another option. </p>
<p>For severe, treatment-resistant cases, IV cyclophosphamide may be considered, although its use is limited due to potentially severe side effects. Treatment plans are individualized based on disease severity and patient response, striving to balance efficacy with minimizing adverse effects. There is a significant unmet need for new treatments for idiopathic inflammatory myositis, as current therapies often do not fully manage the condition.</p>
<p>To know more about idiopathic inflammatory myositis treatment guidelines, visit @ <b><a href="https://www.delveinsight.com/sample-request/idiopathic-inflammatory-myositis-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr" rel="nofollow" target="_blank">Idiopathic Inflammatory Myositis Management </a></b></p>
<p><b>Idiopathic Inflammatory Myositis Pipeline Therapies and Key Companies</b></p>
<ul type="disc"><li>Dazukibart PF-06823859 (anti-beta interferon): Pfizer</li><li>Efgartigimod: Argenx</li><li>SAPHNELO (Anifrolumab): AstraZeneca</li><li>Brepocitinib: Priovant Therapeutics/Pfizer</li><li>HIZENTRA: CSL Behring</li><li>Empasiprubart: Argenx</li><li>Ulviprubart (ABC008): Abcuro, Inc.</li><li>Daxdilimab: Amgen</li><li>Nipocalimab: Janssen</li><li>Froniglutide (PF1801): Immunoforge</li><li>GLPG3667: Galapagos NV</li><li>Enpatoran (M5049): Merck KGaA (EMD Serono Research &amp; Development Institute)</li><li>CABA-201: Cabaletta Bio</li><li>Umbilical Cord Lining Stem Cells (ULSC): Restem</li></ul><p>Discover more about idiopathic inflammatory myositis drugs in development @ <b><a href="https://www.delveinsight.com/sample-request/idiopathic-inflammatory-myositis-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr" rel="nofollow" target="_blank">Idiopathic Inflammatory Myositis Clinical Trials </a></b></p>
<p><b>Idiopathic Inflammatory Myositis Market Dynamics</b></p>
<p>The idiopathic inflammatory myositis market is driven by several key factors, including the <b>increasing prevalence of autoimmune diseases and advancements in diagnostic technologies</b>. As awareness of IIM rises, early detection and <b>accurate diagnosis</b> are becoming more feasible, leading to timely interventions and better patient outcomes. Additionally, the <b>growing understanding of the underlying pathophysiology of IIM</b> is propelling the development of targeted therapies, such as biologics and immune-modulating drugs. The demand for <b>personalized treatments</b> tailored to individual genetic profiles is also pushing innovation in the market. </p>
<p>Furthermore, the <b>rising healthcare expenditure and improved access</b> to specialized care contribute to the market's growth, particularly in developed regions. Finally, <b>ongoing clinical trials and research</b> into novel treatment options continue to fuel optimism for better management and potential cures for IIM, further accelerating the market's expansion. </p>
<p>Potential therapies are being investigated for the treatment of idiopathic inflammatory myositis, and it is safe to predict that the treatment space will significantly impact the idiopathic inflammatory myositis market during the forecast period. Moreover, the <b>anticipated introduction of emerging therapies </b>with improved efficacy and a further <b>improvement in the diagnosis rate</b> are expected to drive the growth of the idiopathic inflammatory myositis market in the 7MM.</p>
<p>However several factors may impede the growth of the idiopathic inflammatory myositis market. One of the primary challenges is the <b>rarity and heterogeneous nature of IIM</b>, which makes it difficult to diagnose and classify accurately. This complicates the development of targeted therapies and slows the recruitment of patients for clinical trials, limiting the scope for market expansion. Additionally, the <b>lack of standardized diagnostic criteria</b> and the <b>complexity of managing the disease</b>, which often involves multidisciplinary care, create barriers to effective treatment and patient outcomes. </p>
<p><b>High costs associated with specialized treatments</b>, coupled with reimbursement issues in many regions, further restrict access to therapies. Moreover, the<b> limited understanding of the disease pathophysiology</b> and the <b>lack of robust biomarkers for monitoring disease progression</b> present additional hurdles for both research and treatment optimization. As a result, these factors collectively impede the growth potential of the IIM market, requiring ongoing innovation and policy support to overcome.</p>
<div><table border="0" cellpadding="1" cellspacing="0" class="prnbcc"><tr><td class="prngen2" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Idiopathic Inflammatory Myositis Market Report Metrics</b></span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span"><b>Details</b></span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Study Period</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">2020–2034</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Coverage</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Idiopathic Inflammatory Myositis Market CAGR</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">21.1 %</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Idiopathic Inflammatory Myositis Market Size in 2023</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">USD 447 Million</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Key Idiopathic Inflammatory Myositis Companies</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Pfizer, Argenx, AstraZeneca, Priovant Therapeutics, CSL Behring, Abcuro, Inc., Amgen, Janssen, Galapagos NV, Immunoforge, Merck KGaA (EMD Serono Research &amp; Development Institute), Cabaletta Bio, Restem, and others</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Key Pipeline Idiopathic Inflammatory Myositis Therapies</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Dazukibart, Efgartigimod, SAPHNELO (Anifrolumab), Brepocitinib, HIZENTRA, Empasiprubart, Ulviprubart (ABC008), Daxdilimab, Nipocalimab, Froniglutide (PF1801), GLPG3667, Enpatoran (M5049), CABA-201, Umbilical Cord Lining Stem Cells (ULSC), and others</span></p>
</td></tr></table></div><p><b>Scope of the </b><b>Idiopathic Inflammatory Myositis</b><b> Market Report</b></p>
<ul type="disc"><li><b>Therapeutic Assessment: </b>Idiopathic Inflammatory Myositis current marketed and emerging therapies</li><li><b>Idiopathic Inflammatory Myositis</b> <b>Market Dynamics:</b> Key Market Forecast Assumptions of Emerging Idiopathic Inflammatory Myositis Drugs and Market Outlook</li><li><b>Competitive Intelligence Analysis:</b> SWOT analysis and Market entry strategies</li><li><b>Unmet Needs, KOL's views, Analyst's views, Idiopathic Inflammatory Myositis Market Access and Reimbursement</b></li></ul><p>Download the report to understand which factors are driving idiopathic inflammatory myositis market trends @ <b><a href="https://www.delveinsight.com/sample-request/idiopathic-inflammatory-myositis-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr" rel="nofollow" target="_blank">Idiopathic Inflammatory Myositis Market Trends</a></b></p>
<p><b>Table of Contents</b></p>
<div><table border="0" cellpadding="1" cellspacing="0" class="prnbcc"><tr><td class="prngen2" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">1</span></p>
</td><td class="prngen3" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Key Insights</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Report Introduction</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Market Overview at a Glance</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">3.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Market Share (%) Distribution of Idiopathic Inflammatory Myositis in 2020</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">3.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Market Share (%) Distribution of Idiopathic Inflammatory Myositis in 2034</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Epidemiology and Market Forecast Methodology</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">5</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Executive Summary</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">6</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Key Events</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">7</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Disease Background and Overview</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">7.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Introduction</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">7.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Clinical Manifestations</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">7.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Etiology and Risk Factors</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">7.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Pathophysiology</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">7.5</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Diagnosis</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">7.5.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Differential Diagnosis</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">7.5.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Diagnostic Criteria</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">7.5.2.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Bohan and Peter's Diagnostic Criteria for Polymyositis and Dermatomyositis</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">7.5.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Diagnostic Algorithm</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">7.5.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Diagnostic Guidelines</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">7.5.4.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">The European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile IIM: 2017</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">7.6</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Treatment</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">7.6.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Treatment Algorithm</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">7.6.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Treatment Guidelines</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">7.6.2.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">British Society for Rheumatology Guideline on Management of Pediatric, Adolescent, and Adult Patients with IIM</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">8</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Patient Journey</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Epidemiology and Patient Population</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Key Findings</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Assumptions and Rationale: The 7MM</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Total Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in the 7MM</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">The US</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9.4.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Total Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in the US</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9.4.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Type-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in the US</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9.4.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Gender-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in the US</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9.4.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Age-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in the US</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9.5</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">EU4 and the UK</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9.5.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Total Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in EU4 and the UK</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9.5.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Type-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in EU4 and the UK</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9.5.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Gender-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in EU4 and the UK</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9.5.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Age-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in EU4 and the UK</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9.6</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Japan</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9.6.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Total Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in Japan</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9.6.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Type-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in Japan</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9.6.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Gender-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in Japan</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">9.6.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Age-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in Japan</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">10</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Marketed Drugs</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">10.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Key Cross Competition</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">10.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">OCTAGAM 10% (Intravenous Immune Globulin [Human]): Octapharma/Pfizer</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">10.2.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Product Description</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">10.2.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Product Profile</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">10.2.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Regulatory Milestone</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">10.2.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Other Developmental Activities</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">10.2.5</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Clinical Trials Information</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">10.2.6</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Safety and Efficacy</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">10.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">VENOGLOBULIN-IH 5% IV (Human Immunoglobulin G): Mitsubishi Tanabe Pharma</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">10.3.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Product Description</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">10.3.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Product Profile</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">10.3.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Regulatory Milestone</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">10.3.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Other Developmental Activities</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">10.3.5</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Clinical Trials Information</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">10.3.6</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Safety and Efficacy</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Emerging Drugs</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Key Cross Competition</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Dazukibart PF-06823859 (anti-beta interferon): Pfizer</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.2.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Description</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.2.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Profile</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.2.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Other Developmental Activities</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.2.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Clinical Trials Information</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.2.5</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Safety and Efficacy</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.2.6</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Analyst Views</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Efgartigimod: Argenx</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.3.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Description</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.3.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Profile</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.3.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Clinical Trials Information</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">SAPHNELO (Anifrolumab): AstraZeneca</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.4.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Description</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.4.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Profile</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.4.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Other Developmental Activities</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.4.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Clinical Trials Information</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.4.5</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Analyst Views</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.5</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Brepocitinib: Priovant Therapeutics/Pfizer</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.5.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Description</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.5.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Profile</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.5.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Other Developmental Activities</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.5.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Clinical Trials Information</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.5.5</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Safety and Efficacy</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.5.6</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Analyst Views</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.6</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">HIZENTRA: CSL Behring</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.6.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Description</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.6.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Profile</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.6.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Other Developmental Activities</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.6.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Clinical Trials Information</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.6.5</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Analysts' View</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.7</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Empasiprubart: Argenx</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.7.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Description</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.7.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Profile</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.7.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Clinical Trials Information</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.8</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Ulviprubart (ABC008): Abcuro, Inc.</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.8.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Description</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.8.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Profile</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.8.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Other Development Activities</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.8.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Clinical Trial Information</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.8.5</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Safety and Efficacy</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.8.6</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Analyst Views</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.9</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Daxdilimab: Amgen</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.9.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Description</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.9.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Profile</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.9.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Other Developmental Activities</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.9.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Clinical Trials Information</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.10</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Nipocalimab: Janssen</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.10.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Description</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.10.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Profile</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.10.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Other Development Activities</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.10.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Clinical Trials Information</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.11</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Froniglutide (PF1801): Immunoforge</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.11.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Description</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.11.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Profile</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.11.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Other Developmental Activities</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.11.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Clinical Trials Information</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.12</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">GLPG3667: Galapagos NV</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.12.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Description</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.12.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Profile</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.12.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Clinical Trials Information</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.12.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Safety and Efficacy</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.13</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Enpatoran (M5049): Merck KGaA (EMD Serono Research &amp; Development Institute)</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.13.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Description</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.13.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Profile</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.13.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Clinical Trials Information</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.14</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">CABA-201: Cabaletta Bio</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.14.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Description</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.14.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Profile</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.14.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Other Developmental Activities</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.14.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Clinical Trials Information</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.14.5</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Safety and Efficacy</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.14.6</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Analyst Views</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.15</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Umbilical Cord Lining Stem Cells (ULSC): Restem</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.15.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Description</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.15.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Drug Profile</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.15.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Clinical Trials Information</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">11.15.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Safety and Efficacy</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Idiopathic Inflammatory Myositis: Market Analysis</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Key Findings</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Key Market Forecast Assumptions</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.2.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Cost Assumptions and Rebates</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.2.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Pricing Trends</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.2.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Analogue Assessment</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.2.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Launch Year and Therapy Uptake</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Market Outlook</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Attribute Analysis</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.5</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Total Market Size of Idiopathic Inflammatory Myositis in the 7MM</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.6</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Total Market Size of Idiopathic Inflammatory Myositis by Therapies in the 7MM</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.7</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Total Market Size of Idiopathic Inflammatory Myositis in the US</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.7.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Total Market Size of Idiopathic Inflammatory Myositis</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.7.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">The Market Size of Idiopathic Inflammatory Myositis by Therapies in the US</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.8</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Market Size of Idiopathic Inflammatory Myositis in EU4 and the UK</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.8.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Total Market Size of Idiopathic Inflammatory Myositis in EU4 and the UK</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.8.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">The Market Size of Idiopathic Inflammatory Myositis by Therapies in EU4 and the UK</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.9</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Market Size of Idiopathic Inflammatory Myositis in Japan</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.9.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Total Market Size of Idiopathic Inflammatory Myositis in Japan</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">12.9.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">The Market Size of Idiopathic Inflammatory Myositis by Therapies in Japan</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">13</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Key Opinion Leaders' Views</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">14</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">SWOT Analysis</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">15</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Unmet Needs</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">16</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Market Access and Reimbursement</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">16.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">The United States</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">16.1.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Centre for Medicare &amp; Medicaid Services (CMS)</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">16.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">In EU4 and the UK</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">16.2.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Germany</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">16.2.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">France</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">16.2.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Italy</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">16.2.4</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Spain</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">16.2.5</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">The United Kingdom</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">16.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Japan</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">16.3.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">MHLW</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">17</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Appendix</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">17.1</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Bibliography</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">17.2</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Acronyms and Abbreviations</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">17.3</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Report Methodology</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">18</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">DelveInsight Capabilities</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">19</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">Disclaimer</span></p>
</td></tr><tr><td class="prngen4" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">20</span></p>
</td><td class="prngen5" colspan="1" rowspan="1"><p class="prnml4"><span class="prnews_span">About DelveInsight</span></p>
</td></tr></table></div><p><b>Related Reports</b></p>
<p><b><a href="https://www.delveinsight.com/report-store/inflammatory-myositis-im-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr" rel="nofollow" target="_blank">Inflammatory Myositis Market</a></b></p>
<p><b>Inflammatory Myositis Market Insights, Epidemiology, and Market Forecast </b><b>– 2034 </b>report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key inflammatory myositis companies, including <b>CSL Behring, Immunoforge Co. Ltd., Argenx, Janssen, Abcuro, Inc., Horizon Therapeutics, Merck KGaA, Galapagos NV, Priovant Therapeutics, Roivant, Alexion Pharmaceuticals, Pfizer, Kezar Life Sciences</b><b>, </b>among others.</p>
<p><b><a href="https://www.delveinsight.com/report-store/myositis-pipeline-insight?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr" rel="nofollow" target="_blank">Myositis Pipeline</a></b></p>
<p><b>Myositis Pipeline Insight – 2024</b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myositis companies, including <b>GlaxoSmithKline, Corbus Pharmaceuticals, Abcuro, Inc., Orphazyme, Bristol-Myers Squibb, Kezar Life Sciences, Inc., Horizon Therapeutics, <span class="xn-person">Viela Bio</span>, Paean Biotechnology Inc., Alexion Pharmaceuticals, Janssen Biotech, CSL Behring, Pfizer, Roche, </b>among others.</p>
<p><b><a href="https://www.delveinsight.com/report-store/inclusion-body-myositis-market?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr" rel="nofollow" target="_blank">Inclusion Body Myositis Market</a></b></p>
<p><b>Inclusion Body Myositis</b><b> Market Insight, Epidemiology, and Market Forecast – 2034 </b>report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key inclusion body myositis companies, including<b> Acceleron Pharma Inc, KPI Therapeutics Inc, Milo Biotechnology LLC, Nobelpharma Co Ltd, Orphazyme ApS, Ultragenyx Pharmaceutical Inc, </b>among others.</p>
<p><b><a href="https://www.delveinsight.com/report-store/inclusion-body-myositis-pipeline-insight?utm_source=cision&amp;utm_medium=pressrelease&amp;utm_campaign=spr" rel="nofollow" target="_blank">Inclusion Body Myositis Pipeline</a></b></p>
<p><b>Inclusion Body Myositis Pipeline Insight – 2024</b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key inclusion body myositis companies, including <b>Acceleron Pharma Inc, KPI Therapeutics Inc, Milo Biotechnology LLC, Nobelpharma Co Ltd, Orphazyme ApS, Ultragenyx Pharmaceutical Inc, </b>among others.</p>
<p><b>About DelveInsight</b></p>
<p>DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve<b>.</b></p>
<p><b>Contact Us<br></br></b><span class="xn-person">Shruti Thakur</span><br></br><a href="mailto:info@delveinsight.com" rel="nofollow" target="_blank">info@delveinsight.com</a> <br></br>+14699457679<br></br><a href="https://www.delveinsight.com/" rel="nofollow" target="_blank">www.delveinsight.com</a> </p>
<p>Logo: <a href="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" rel="nofollow" target="_blank">https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg</a></p>
<p> </p>






<p id="PURL"><img alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN89279&amp;sd=2025-01-06" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/idiopathic-inflammatory-myositis-market-predicted-to-show-positive-growth-at-a-tremendous-cagr-of-21-1-by-2034--delveinsight-302342709.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/idiopathic-inflammatory-myositis-market-predicted-to-show-positive-growth-at-a-tremendous-cagr-of-21-1-by-2034--delveinsight-302342709.html</a></p>

<img alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN89279&amp;Transmission_Id=202501061731PR_NEWS_EURO_ND__EN89279&amp;DateId=20250106" style="border:0px; width:1px; height:1px;"></img>